AngioDynamics Stock Earnings Estimates Cut by HC Wainwright

AngioDynamics, Inc. (NASDAQ:ANGO) – Equities research analysts at HC Wainwright lowered their Q2 2027 earnings per share (EPS) estimates for AngioDynamics in a report released on Tuesday, October 13th. HC Wainwright analyst Y. Chen now expects that the medical instruments supplier will post earnings per share of ($0.11) for the quarter, down from their previous forecast of ($0.10). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for AngioDynamics’ Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.28) EPS, Q1 2028 earnings at ($0.09) EPS, Q2 2028 earnings at ($0.05) EPS, Q3 2028 earnings at ($0.02) EPS, Q4 2028 earnings at $0.02 EPS and FY2028 earnings at ($0.15) EPS.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.07. The firm had revenue of $80.92 million during the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Several other brokerages have also recently commented on ANGO. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price objective on shares of AngioDynamics in a report on Friday, October 9th. Finally, Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, AngioDynamics presently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

AngioDynamics Trading Up 1.4%

Shares of NASDAQ ANGO opened at $11.05 on Thursday. The firm has a market capitalization of $464.65 million, a PE ratio of -14.17 and a beta of 0.30. AngioDynamics has a 1 year low of $9.39 and a 1 year high of $16.29. The firm’s 50-day moving average is $15.08 and its 200-day moving average is $13.12.

Hedge Funds Weigh In On AngioDynamics

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in AngioDynamics during the second quarter worth about $49,480,000. Armistice Capital LLC increased its stake in shares of AngioDynamics by 3.9% in the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock valued at $21,828,000 after acquiring an additional 64,000 shares during the last quarter. Weber Capital Management LLC ADV bought a new stake in shares of AngioDynamics in the 2nd quarter valued at about $17,649,392. Bastion Asset Management Inc. increased its stake in shares of AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock valued at $14,107,000 after acquiring an additional 194,822 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of AngioDynamics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock valued at $10,786,000 after acquiring an additional 32,476 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

Insider Activity at AngioDynamics

In related news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.00% of the stock is currently owned by company insiders.

Key AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright’s $18 target implies substantial upside from the recent $11.05 reference price, and the firm continues to recommend buying AngioDynamics shares. HC Wainwright Has Lowered Expectations for AngioDynamics Stock Price
• Positive Sentiment: The analyst’s longer-term outlook points to improving results: projected losses narrow from $0.28 per share in fiscal 2027 to $0.15 in fiscal 2028, with a projected return to quarterly profitability of $0.02 per share in the fourth quarter of fiscal 2028.
• Neutral Sentiment: HC Wainwright forecasts fiscal 2028 quarterly EPS of ($0.09), ($0.05), ($0.02), and $0.02, respectively. The estimates suggest gradual progress but imply AngioDynamics is not expected to be profitable for the full fiscal year.
• Negative Sentiment: HC Wainwright reduced its fiscal 2027 EPS forecast to a loss of $0.28 from $0.27 and cut estimates for the second quarter of fiscal 2027 to a $0.11 loss from $0.10, the third quarter to a $0.10 loss from $0.06, and the fourth quarter to a $0.02 loss from a prior $0.01 profit. These revisions indicate weaker near-term earnings expectations.
• Negative Sentiment: The firm also lowered its price target from $19 to $18, even while retaining its Buy rating. The target reduction may limit enthusiasm, although the revised objective still indicates meaningful potential appreciation. Benzinga and The Fly analyst update

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.